Biohaven Ltd.

NYSE:BHVN Stock Report

Market Cap: US$3.7b

Biohaven Management

Management criteria checks 2/4

Biohaven's CEO is Vlad Coric, appointed in May 2022, has a tenure of 2.58 years. directly owns 3.13% of the company’s shares, worth $114.87M. The average tenure of the management team and the board of directors is 2.3 years and 2.3 years respectively.

Key information

Vlad Coric

Chief executive officer

US$6.8m

Total compensation

CEO salary percentagen/a
CEO tenure2.6yrs
CEO ownership3.1%
Management average tenure2.3yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Biohaven's Revenue Path: SCA And Obesity Therapies

Nov 29

Biohaven: A Complicated Tale

Oct 11

Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst

Sep 23

Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment

Jul 26

Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge

May 18

We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Apr 06
We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate

Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Mar 01
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)

Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)

Feb 28

Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)

Dec 08

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Dec 04
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True

Sep 27

Biohaven's Valuation Challenge: Weighing Potential Against Setbacks

Aug 28

Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Jul 22
Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation

Biohaven: A Promising Investment In Innovative Neurological Therapies

Jun 14

Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache

Jun 06

Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Apr 06
Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?

Biohaven's spinal muscular atrophy therapy gets FDA fast track status

Feb 21

Biohaven Ltd: Assessing The Spinoff

Dec 07

Biohaven Non-GAAP EPS of -$1.25

Nov 09

CEO Compensation Analysis

How has Vlad Coric's remuneration changed compared to Biohaven's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$804m

Jun 30 2024n/an/a

-US$747m

Mar 31 2024n/an/a

-US$517m

Dec 31 2023US$7mn/a

-US$408m

Sep 30 2023n/an/a

-US$465m

Jun 30 2023n/an/a

-US$431m

Mar 31 2023n/an/a

-US$544m

Dec 31 2022US$7mUS$200k

-US$570m

Compensation vs Market: Vlad's total compensation ($USD6.82M) is about average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Vlad's compensation has increased whilst the company is unprofitable.

CEO

Vlad Coric (53 yo)

2.6yrs

Tenure

US$6,819,189

Compensation

Dr. Vladimir Coric, M.D., also known as Vlad, is an Independent Director at Revance Therapeutics, Inc. since March 01, 2023. He is Director at Pyramid Biosciences Inc. since August 2020. He had been Indepe...

Leadership Team

NamePositionTenureCompensationOwnership
Vladimir Coric
Chairman & CEO2.6yrsUS$6.82m3.13%
$ 114.9m
Matthew Buten
Chief Financial Officerno dataUS$2.76m0.19%
$ 6.9m
Bruce Car
Chief Scientific Officer2.3yrsUS$2.58m0.032%
$ 1.2m
Kimberly Gentile
Senior Vice President of Clinical Operationsno dataUS$2.56m0.095%
$ 3.5m
Deb Young
Director of Regulatory Affairs & Operations1.9yrsno datano data
George Clark
VP & Chief Accounting Officerno datano datano data
Jennifer Porcelli
Vice President of Investor Relationsno datano datano data
Warren Volles
General Counsel & Chief Legal Officerno datano datano data
Clifford Bechtold
Presidentno datano datano data
John Tilton
Chief Commercial Officer of Rare Diseasesno datano datano data
Chris Barrett
Senior Vice President of Commercial Strategyno datano datano data
Gilbert L'italien
Senior Vice President of GHEOR & Epidemiologyno datano datano data

2.3yrs

Average Tenure

57yo

Average Age

Experienced Management: BHVN's management team is considered experienced (2.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Vladimir Coric
Chairman & CEO2.6yrsUS$6.82m3.13%
$ 114.9m
Douglas Gray
Corporate Secretary & Directorno datano datano data
John Childs
Independent Director2.3yrsUS$555.94k6.41%
$ 235.0m
Julia Gregory
Independent Director2.3yrsUS$567.94k0.025%
$ 930.6k
Robert Hugin
Independent Director2.3yrsUS$562.94k0.013%
$ 470.1k
Gregory Bailey
Independent Director2.3yrsUS$545.94k1.6%
$ 58.7m
Michael Heffernan
Lead Independent Director2.3yrsUS$597.94k0.015%
$ 550.4k
Richard B. Lipton
Member of Scientific Advisory Boardno datano datano data
John Krystal
Member of Scientific Advisory Boardno datano datano data
Irina Antonijevic
Independent Director2.3yrsUS$542.94k0.0025%
$ 92.0k
Kishan Mehta
Director2.3yrsUS$535.94k0.022%
$ 821.7k
Gerard Sanacora
Member of Scientific Advisory Boardno datano datano data

2.3yrs

Average Tenure

64yo

Average Age

Experienced Board: BHVN's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 08:29
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Biohaven Ltd. is covered by 16 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Brian SkorneyBaird
Jason Matthew GerberryBofA Global Research
Thomas ShraderBTIG